Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
The company will resume development of islatravir for HIV treatment but abandons monthly oral PrEP.
Injectable lenacapavir is indicated for people with multidrug-resistant virus who have run out of treatment options.
Lenacapavir, a long-acting HIV capsid inhibitor, is back on track after the Food and Drug Administration lifted a clinical hold on the drug.
The injectable antiretroviral could potentially be taken once every six months for HIV treatment or PrEP.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.